A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy.

PubWeight™: 1.15‹?› | Rank: Top 10%

🔗 View Article (PMC 2957289)

Published in Clin Transplant on December 01, 1994


R Shapiro1, M Jordan, V Scantlebury, C Vivas, J Fung, J McCauley, A Tzakis, P Randhawa, A J Demetris, W Irish

Author Affiliations

1: Pittsburgh Transplantation Institute, Dept. of Surgery, University of Pittsburgh Health Science Center of Pittsburgh, PA, U.S.A.

Articles cited by this

Kidney transplantation under FK 506. JAMA (1990) 7.45

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

RS-61443--a phase I clinical trial and pilot rescue study. Transplantation (1992) 1.97

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol (1993) 1.32

Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc (1991) 1.24

The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc (1991) 1.16

Historical development of brequinar sodium as a new immunosuppressive drug for transplantation. Transplant Proc (1993) 0.95

Japanese study of FK 506 on kidney transplantation: results of late phase II study. Transplant Proc (1993) 0.95

Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. Transplant Proc (1991) 0.94

Cadaveric renal transplantation under the American organ allocation system. Contrib Nephrol (1989) 0.93

Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression. Transplant Proc (1993) 0.92

Human islet allotransplantation under FK 506. Transplant Proc (1991) 0.89

Bredinin treatment in clinical kidney allografting. Transplantation (1984) 0.85

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09

Kidney transplantation under FK 506. JAMA (1990) 7.45

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Liver transplantation (1). N Engl J Med (1989) 4.53

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol (1996) 3.20

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95

Liver transplantation (2). N Engl J Med (1989) 2.93

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85

Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82

Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear export pathway. J Virol (2001) 2.76

The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48

Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Characterization of influenza virus RNA complete transcripts. Virology (1982) 2.31

Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

Homeostasis of alpha beta TCR+ T cells. Nat Immunol (2000) 2.29

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28

Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25